ARDENT HEALTH PARTNERS INC SEC Filings

Stephen C. Petrovich, Executive Vice President, General Counsel and Assistant Secretary of Ardent Health, Inc. (ARDT), reported a routine share disposition on 09/25/2025. The filing shows 788 shares were withheld to satisfy tax withholding upon vesting of restricted stock units at a closing price of $13.19, and after that transaction Mr. Petrovich directly beneficially owned 718,303 shares. In addition, the filing discloses two family trusts each holding 186,225 shares, which the reporting person disclaims beneficial ownership of except for any pecuniary interest. The form is a standard Section 16 report documenting an internal tax-related share settlement rather than an open-market sale.

David Raynor Byers, Senior Vice President & Chief Accounting Officer of Ardent Health, Inc. (ARDT), reported a routine disposition of common stock on 09/25/2025. The filing shows 524 shares were disposed under Code F (withholding to pay taxes upon vesting of restricted stock units) at a reported price equal to the closing stock price on 09/25/2025 of $13.19. After the withholding, Mr. Byers beneficially owns 111,791 shares directly. The Form 4 was signed by an attorney-in-fact on 09/30/2025.

Ardent Health, Inc. amended its term loan and ABL credit facilities with Bank of America and other lenders. The Term Loan Amendment refinanced outstanding term loans in full, extended the term loan maturity from August 24, 2028 to September 18, 2032, reduced the applicable interest spread by 50 basis points (from Term SOFR+2.75% to Term SOFR+2.25%, and from base rate+1.75% to base rate+1.25%), and expanded fixed-dollar negative covenant baskets. The ABL Amendment aligned certain fixed-dollar negative covenant baskets with the term loan changes but did not extend the ABL maturity or make other material changes. The full amendment texts are filed as exhibits and govern the detailed terms.

Ardent Health, Inc. operates a network of 30 acute care hospitals and approximately 280 sites of care across six states with 1,875 employed and affiliated providers as of June 30, 2025. The company uses a joint-venture model in which it is typically the majority owner and day-to-day operator, partnering with academic and not-for-profit systems to expand market presence and clinical services. EGI-AM Investments, L.L.C. owned approximately 54.0% of outstanding common stock, making EGI-AM the company’s controlling stockholder under NYSE rules. The filing discloses a table of selling stockholders showing large share blocks (for example, 77,246,499 shares representing 54.0%) and various other holders with specified share counts and percentages. The prospectus lists exhibits, underwriting and legal opinions, audit consents from Ernst & Young LLP, and a registration fee table.

Ardent Health, Inc. (NYSE: ARDT) filed an 8-K disclosing the immediate departure of David Schultz, President, Hospital Operations, effective June 16 2025. The company classified the exit as a “Qualifying Termination” under its Executive Severance Plan, making Mr. Schultz eligible for severance payments and related benefits, subject to standard plan conditions such as non-compete and non-solicitation covenants.

The filing provides no quantitative detail on payout size, claw-back triggers, or succession plans. Mr. Schultz had overseen the hospital segment, a core operating unit that drives the majority of Ardent’s revenue. Governance protocol appears to have been followed—compensation terms reference disclosures in the April 8 2025 proxy statement and the Q2 2024 10-Q exhibit that contains the Severance Plan.

Investment relevance:

• Unanticipated C-suite turnover can disrupt execution of operational initiatives, regulatory compliance, and cost-containment programs, potentially affecting near-term margin trajectory.
• Because no interim or permanent replacement was announced, investors face visibility risk on leadership continuity in hospital operations.
• Cash severance outflows could be modest relative to Ardent’s scale, but exact magnitude is not provided, limiting assessment of liquidity impact.